ecancermedicalscience最新文献

{"title":"Treatment outcomes of paediatric chest wall Ewing's sarcoma; report from tertiary care cancer center.","authors":"Rabia Wali, Sadia Anjum, Sumera Abdul Kareem, Najma Shaheen","doi":"10.3332/ecancer.2026.2117","DOIUrl":"10.3332/ecancer.2026.2117","url":null,"abstract":"<p><strong>Introduction: </strong>Chest wall Ewing sarcoma (EWS) is a common paediatric malignant tumour affecting the chest wall, accounting for about 10% of all EWS patients. Treatment typically involves intense chemotherapy, complete surgical resection when possible and/or radiation. The EWS of the chest wall has a reported 5-year survival ranging between 40% and 60% in most studies. The following study evaluated the effect of different treatment modalities on survival outcomes in paediatric patients.</p><p><strong>Methodology: </strong>This is a single-center retrospective cohort study that included 46 patients diagnosed with chest wall EWS between January 2011 and December 2023 at Shaukat Khanum Memorial Cancer Hospital and Research Center. Approval was obtained from the Institutional Review Board for this study. The 5-year follow up period and outcomes were analysed using the SPSS.</p><p><strong>Results: </strong>The cohort included 46 patients (56% female, 44% male) with a median age of 10 years. Non-metastatic disease was observed in 94% of the patients. The compressed vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide chemotherapy regimen showed better outcomes, with a 48% survival rate compared with 38% for vincristine, doxorubicin, actinomycin, ifosfamide and etoposide. Negative surgical margins were associated with a 56% survival rate. 5-year overall survival (OS) of 42.5% and event-free survival (EFS) of 39%. Both the OS and EFS were better in patients who had surgery alone as local control (LC).</p><p><strong>Conclusion: </strong>Outcomes in patients who had surgery as LC did better in this study. Early recognition and referral may help in reducing the tumour burden so that good LC with surgical R-zero resection is possible.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2117"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of adding vincristine to procarbazine-lomustine in patients with gliomas: insights from current evidence.","authors":"Viviana Pinzón-Ramírez, Luis E Cueva-Cañola, Dilmareth E Natera, Helder Edgar Aldo-Chávez Olivera, Oscar Eduardo Camacho-Hernández, Andrea C Beltran-De la Fuente, Sergio Alexis Ramirez-Alvarez, Einstein Yhair Gallardo Cubas, Giomar Vilca Flores, Mauricio E Gamez, Leonardo Rangel Castilla","doi":"10.3332/ecancer.2026.2115","DOIUrl":"10.3332/ecancer.2026.2115","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Temozolomide (TMZ) is the standard chemotherapy for gliomas due to good tolerability. Clinical studies suggest a combination of procarbazine, lomustine (CCNU) and vincristine (PCV) provides superior survival and progression delay, but toxicities limit use. Given the ongoing debate over the role of vincristine in glioma chemotherapy amid the dominance of TMZ, simplified procarbazine and CCNU (PC) regimens warrant renewed evaluation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Three databases were searched up to August 2025 to identify studies that directly compared PC and PCV in patients with low-grade and high-grade gliomas. Outcomes included progression-free survival (PFS), overall survival (OS) and treatment-related toxicities. Hazard ratios (HRS) and relative risks (RRS) were then pooled using a random-effects model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In a total population of 301 patients with low- and high-grade gliomas, PC significantly reduced the risk of disease progression compared with PCV (HR = 0.72, 95% confidence interval (CI): 0.53-0.98; &lt;i&gt;p&lt;/i&gt; = 0.04) and OS was also significantly longer with PC (HR = 0.59, 95% CI: 0.37-0.95; &lt;i&gt;p&lt;/i&gt; = 0.03). Neurotoxicity (RR = 0.12, 95% CI: 0.02-0.63; &lt;i&gt;p&lt;/i&gt; = 0.01) and treatment discontinuation (RR = 0.11, 95% CI: 0.02-0.80; &lt;i&gt;p&lt;/i&gt; = 0.03) were less frequent with PC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;With the limited evidence available to date, we found that PC achieved significantly longer PFS and OS than PCV, while maintaining a better safety profile. We recommend further well-designed and adequately powered randomised clinical trials directly comparing TMZ, PC and PCV to determine which patient populations and glioma subtypes - according to the current World Health Organisation 2021 classification - derive the greatest survival benefit and tolerability from each regimen.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Key points: &lt;/strong&gt;Procarbazine-lomustine combination (PC) shows superior progression-free survival and overall survival versus procarbazine, lomustine and vincristine (PCV) in gliomas.Omitting vincristine may improve efficacy and reduce neurotoxicity.Findings suggest PC could be a safer alternative, pending confirmation by randomised controlled trials.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Importance of the study: &lt;/strong&gt;This meta-analysis is the first to directly evaluate whether vincristine is necessary within the procarbazine, lomustine and vincristine (PCV) regimen for gliomas. By synthesising data from three retrospective cohorts, it demonstrates that the procarbazine-lomustine combination (PC) achieved significantly longer progression-free and overall survival compared with PCV, while markedly reducing neurotoxicity and treatment discontinuation. These findings challenge the traditional view that vincristine is an indispensable component of chemotherapy for diffuse gliomas. Given that temozolomide has become the preferred agent in contemporary practice, clarifying the relative contributions of PC, PCV","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2115"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing delays in radiotherapy initiation post CT simulation: a quality improvement study from a rural cancer center in India.","authors":"Pragyat Thakur, Nagarjun Ballari, Anureet Kaur, Tapas Kumar Dora, I Vedamanasa, Arshdeep Kaur, Ashish Gulia","doi":"10.3332/ecancer.2026.2116","DOIUrl":"10.3332/ecancer.2026.2116","url":null,"abstract":"<p><p>Radiation therapy (RT) is a cornerstone in the treatment of solid tumours, with more than half of all cancer patients requiring it for curative or palliative intent. However, delays in initiating RT after CT simulation (CT sim) can significantly impact clinical outcomes by increasing recurrence risk, triggering re-simulation due to anatomical shifts and causing psychological and logistical distress for patients and caregivers. This prospective quality improvement (QI) study was conducted at a rural cancer center in India from April to December 2022, aiming to reduce the time from CT sim to RT initiation. Using the A3 methodology in collaboration with Enable Quality, Improve Patient Care India, Stanford Medicine and the National Cancer Grid, a root cause analysis was conducted, followed by key driver identification via Pareto analysis. A series of Plan-Do-Study-Act (PDSA) cycles led to targeted interventions, including written standard operating procedures (SOPs) for scheduling, standardised patient instructions, clearly defined staff roles and stakeholder education. Data from 200 patients planned for radical treatment were analysed weekly, with treatment timelines plotted on a run chart. At baseline, the median delay from simulation to treatment initiation was 18 days. After implementation of interventions in July 2022, this was reduced to 12 days by September and further to 10 days by November, a 44.4% reduction . Additionally, the re-simulation rate dropped from 10% to less than 1%. No patient experienced a delay beyond the prescribed date, and importantly, staff feedback confirmed that the revised workflow did not increase perceived workload. The interventions were institutionalised through SOPs and monitored via real time dashboards, ensuring sustainability into 2024. This study demonstrates that targeted, system-level interventions developed using accessible QI methodologies can lead to meaningful reductions in RT delays and operational inefficiencies in low-resource environments. The model is feasible, cost-effective and adaptable to other cancer centers aiming to optimise timely RT delivery and improve patient outcomes.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2116"},"PeriodicalIF":1.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extent of cancer at the time of diagnosis in older adults: a cohort of a Chilean cancer insurance program (2018-2022).","authors":"Sergio Muñoz-Navarro, Christian Caglevic, Jorge Sapunar","doi":"10.3332/ecancer.2026.2114","DOIUrl":"10.3332/ecancer.2026.2114","url":null,"abstract":"<p><strong>Introduction: </strong>In Chile, the cancer mortality rate ratio between older adults and individuals under 65 years of age is 12.14. This excess mortality may be attributed to cancer-specific factors or comorbidities commonly observed in older adults.</p><p><strong>Objective: </strong>To compare the frequency of advanced clinical stages at diagnosis, for the five most epidemiologically significant malignant neoplasms - breast, prostate, lung, colorectal and gastric cancers - between older adults (≥65 years) and individuals between 40 and 64 years of age.</p><p><strong>Methods: </strong>We conducted a retrospective study of health insurance beneficiaries, identifying new cases of breast, prostate, lung, colorectal and gastric cancers diagnosed between 2018 and 2022. Age-adjusted incidence rates and the proportion of advanced clinical stages (III and IV) were compared between older adults and younger individuals.</p><p><strong>Results: </strong>The cancer incidence rate ratio between older and younger adults ranged from 1.77 to 6.315 (p < 0.0001). For lung, colorectal and gastric cancers, the majority of patients were diagnosed at advanced clinical stages. Conversely, for breast and prostate cancers, the proportion of advanced stages was 18.07% and 40.37%, respectively. Older adults exhibited a significantly higher risk of advanced-stage diagnosis only for gastric cancer.</p><p><strong>Discussion: </strong>The incidence of major cancers was markedly higher among individuals aged 65 and older. However, there were no significant differences in the proportion of advanced clinical stages at diagnosis across most cancer types, except for gastric cancer. The elevated cancer-related mortality observed in older adults may be more closely associated with comorbid conditions rather than the stage at diagnosis.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2114"},"PeriodicalIF":1.5,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A high-resolution geospatial analysis of radiation therapy access in the Philippines.","authors":"Juzzel Ian Zerrudo, Fjorda Kim Rubian-Zerrudo","doi":"10.3332/ecancer.2026.2113","DOIUrl":"10.3332/ecancer.2026.2113","url":null,"abstract":"<p><strong>Background: </strong>In 2019, the Philippines enacted the National Integrated Cancer Control Act (NICCA) to decentralise cancer care. However, implementation remains limited by a lack of data to guide effective resource allocation. This study provides high-resolution, quantitative baseline data of radiotherapy (RT) accessibility in Luzon, the country's largest island group, to identify priority areas for infrastructure development.</p><p><strong>Methods: </strong>A cross-sectional geospatial analysis for 698 municipalities was conducted using the Enhanced Two-Step Floating Catchment Area (E2SFCA) model, integrating provider capacity, population demand and calibrated travel time. Access was modelled under two scenarios: one including all 43 RT facilities and another restricted to the 12 public centres. To quantify financial toxicity, we developed a novel metric, the travel-cost-to-wage ratio. We performed spatial autocorrelation and multivariable regression analyses to identify geographic clusters and key determinants of access.</p><p><strong>Results: </strong>Profound inequities in RT access were identified. Considering all facilities, 240 municipalities (34.4%) home to 7.5 million people, had no potential access within a 120-minute catchment. The public-only scenario revealed a near-total system inadequacy, with 12.2 million people lacking access. Spatial analysis confirmed a stark core-periphery pattern, with a well-served core centred around the national capital and along the primary north-south expressway network, contrasted with vast, statistically significant 'RT deserts' in outlying regions. For 4.9 million people, a single round-trip to the nearest public facility costs more than a day's minimum wage; this travel-cost-to-wage ratio was the strongest predictor of access (odds ratio = 0.83, p < 0.001).</p><p><strong>Conclusion: </strong>Spatial access to RT in Luzon is profoundly inequitable, characterised by a stark core-periphery pattern and an inadequate public system that leaves millions reliant on private care or entirely without access. This study provides a data-driven roadmap to guide the strategic implementation of NICCA, ensuring that future resource allocation targets the identified RT deserts to address these critical gaps in cancer care.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2113"},"PeriodicalIF":1.5,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer clinical trials in low- and middle-income countries (LMICs).","authors":"Adnan-Mustafiz Chowdhury, Sattam A Halaseh, Debora Joseph, Abel I Abel, Nikita Jha, Amro Al-Karadsheh, Hakam Al-Karadsheh, Omar A Salem, Sama F Salaitah, Noor M Arman, Georges Rizkallah","doi":"10.3332/ecancer.2026.2112","DOIUrl":"10.3332/ecancer.2026.2112","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most diagnosed malignancy worldwide and a leading cause of cancer-related mortality in women. Clinical trials underpin advances in prevention, diagnosis and treatment; however, the landscape of breast cancer trials in low- and middle-income countries (LMICs) remains insufficiently characterised. This study aimed to describe the scope, design, interventions and funding of breast cancer clinical trials conducted in LMICs between January 2010 and December 2020.</p><p><strong>Methods: </strong>We searched the Cochrane Central Register of Controlled Trials on 15 November 2023 for trials using the keywords 'breast cancer', 'breast adenocarcinoma' and 'breast tumour'. Trials were classified by World Bank income category. Extracted variables included study design, primary purpose, time perspective, observational model, trial phase, intervention type, sample size, status, reason for termination, funding source and centre type. Descriptive statistics summarised trial characteristics.</p><p><strong>Results: </strong>A total of 333 breast cancer trials were identified; Two trials (0.6%) were conducted in low-income countries and 331 (99.4%) in lower-middle-income countries; no trials conducted exclusively in upper-middle-income countries were identified within the registry during the study period. Most trials were interventional (85.3%), prospective (95.8%) and treatment-focused (71.5%). Drug-based interventions predominated (64.9%). Funding was primarily from pharmaceutical or biotechnology companies (53.2%), followed by academic or institutional (university-based) sources (39.6%). Only 7.5% of trials addressed prevention, screening and supportive care. Multicentre trials accounted for 53.8%, single-centre 46.3%.</p><p><strong>Conclusion: </strong>Breast cancer trials in LMICs are predominantly interventional, pharmaceutically-funded and concentrated in lower-middle-income settings. There remains a substantial paucity of trials from low-income countries and in non-treatment domains such as prevention, screening and supportive care.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2112"},"PeriodicalIF":1.5,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives and preferences on palliative chemotherapy-immunotherapy in gallbladder cancer patients.","authors":"Koreddi A Dora, Vaka Rajashekhar, Mahadevapura R Kaushik, Gaurav Vora, Arti Sarin, Amol Patel","doi":"10.3332/ecancer.2026.2111","DOIUrl":"10.3332/ecancer.2026.2111","url":null,"abstract":"<p><strong>Background: </strong>Patients' perspective and preferences about the chemotherapy are not known. This study investigates the perspectives and treatment preferences of Indian gallbladder (GBC) patients.</p><p><strong>Methods: </strong>A prospective 18-month study at a tertiary cancer center in Mumbai enrolled patients with histologically confirmed GBC receiving palliative chemotherapy, who were counselled in a structured format regarding disease, treatment options, outcomes and drug costs. Data were collected through structured interviews using quality-of-life and decision-making questionnaires. Descriptive statistics were used to analyse patient responses. A pilot sample of 30 patients was used to assess whether ≥90% prioritise survival as the primary expectation from chemo-immunotherapy. Using an exact one-sided binomial design, ≤23 responses favouring survival would indicate the proportion is <90% and warrant further study. We also evaluated the psychological distress among these patients.</p><p><strong>Results: </strong>Among 30 participants (56.67% female), 83.33% were of advanced stage. Baseline demographics is depicted. Treatment priorities varied: 40% preferred life prolongation, 23.33% favoured symptom relief and 36.67% valued both equally. Financial burden strongly influenced decisions about immunotherapy, only 6.67% were willing to pay ₹35 lakhs out-of-pocket for a 1.5-month gain, while 100% would take treatment if it were government-funded. Emotional distress was significant, with a mean NCCN score of 6.21 ± 1.80. Major concerns included financial strain (42%), fear (45%) and depression (33%).</p><p><strong>Conclusion: </strong>Twenty-three percent of patients favoured only symptom relief as a treatment when they were educated about the outcomes. A larger study is warranted to further consolidate our findings.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2111"},"PeriodicalIF":1.5,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of smoking cessation on survival and treatment tolerability in advanced non-small cell lung cancer: a single-center experience from Morocco.","authors":"Intissar Belrhali, Ibrahim El Ghissassi, Boutaina Cherkaoui, Oumaima Lamsyah, Khaoula Ouchen, Soufiane Bel Rhali, Saoussane Kharmoum, Sarah Naciri, Hanane Inrhaoun, Siham Lkhoyaali, Salma Najm, Hind Mrabti, Hassan Errihani","doi":"10.3332/ecancer.2026.2110","DOIUrl":"10.3332/ecancer.2026.2110","url":null,"abstract":"<p><strong>Background: </strong>Smoking cessation following a lung cancer diagnosis presents a dual challenge, as patients must cope with both the emotional burden of cancer and nicotine dependence. This study aimed to evaluate the impact of smoking cessation on overall survival (OS) and treatment tolerability in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>This retrospective cohort study included patients with stage III-IV NSCLC treated at the National Institute of Oncology, Rabat, Morocco, between January 2022 and December 2023. Patients were classified as ex-smokers (n = 60), who quit smoking at diagnosis or active smokers (n = 40), who continued smoking thereafter. Smoking cessation support was individualised and included medical counselling, psychological support, nicotine replacement therapy and referral to specialised cessation consultations. Outcomes assessed included treatment response, adverse events and OS.M.</p><p><strong>Results: </strong>Among 100 patients (mean age 69 ± 9 years), there were no significant differences between groups in disease stage (p = 0.70) or histology (p = 0.63). Treatment intolerance occurred in 55% of patients, with adverse events more frequent in active smokers (39%) than in ex-smokers (16%). Haematologic toxicity, particularly neutropenia, was significantly higher in active smokers (p < 0.001). Notably, patients who quit smoking during treatment experienced improved treatment tolerability. Median OS was 10 months overall, with longer survival in ex-smokers (11 months) compared with active smokers (7 months) (log-rank p < 0.001).</p><p><strong>Conclusion: </strong>Smoking cessation at diagnosis is associated with reduced treatment-related toxicity and improved survival in advanced NSCLC, supporting its role as an independent prognostic factor and a priority in clinical management.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2110"},"PeriodicalIF":1.5,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic association of <i>IL-1B-511</i> (C/T), <i>TNF-A-308</i> (G/A) and <i>IL-10-1082</i> (G/A) with gastric cancer risk in Colombian populations.","authors":"Kevin Guzmán, Vanessa Pabón, Andrés Angulo, Luis E Bravo, Arsenio Hidalgo, Carol Rosero, Alvaro Pazos","doi":"10.3332/ecancer.2026.2107","DOIUrl":"10.3332/ecancer.2026.2107","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) incidence varies markedly across Colombia. Host genetic polymorphisms in cytokine genes modulate the inflammatory response to Helicobacter pylori and may influence disease progression.</p><p><strong>Objective: </strong>To evaluate IL-1B-511, IL-10-1082 and TNF-A-308 polymorphisms and their association with gastric precursor lesions in Colombian populations with contrasting GC risk.</p><p><strong>Methods: </strong>We studied 160 dyspeptic patients from Túquerres (high risk) and 105 from Tumaco (low risk). Gastric lesions were classified using the Sydney system. Cytokine polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism and sequencing. Associations were assessed using logistic regression.</p><p><strong>Results: </strong>The IL-1B-511TT and IL-10-1082AA genotypes were significantly more frequent in Túquerres than in Tumaco (p < 0.05). Individuals carrying the IL-10-1082AG genotype had a significantly higher risk of gastric atrophy (odds ratio = 5.45; 95% confidence interval, 1.0-30.59).</p><p><strong>Conclusion: </strong>IL-10-1082AG is associated with increased risk of gastric atrophy in high-risk Colombian populations, supporting its potential role as a biomarker of GC susceptibility.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2107"},"PeriodicalIF":1.5,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Community-based peer education as a tool for the prevention of breast cancer: a narrative review.","authors":"Rachael O Oduyemi, Chizoma Millicent Ndikom, Gloria Oluwakorede Alao, Iyanuoluwa O Ojo, Faith Ayomide Ajayi, Damilola Ajibade, Abdullahi Suleiman, Hameedah Ayomide Gbadamosi, Oluwadamilare Akingbade","doi":"10.3332/ecancer.2026.2108","DOIUrl":"10.3332/ecancer.2026.2108","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a major threat to women, especially in low-resource settings like Nigeria, where awareness and screening are limited. Peer education may offer a practical way to improve early detection and prevention in these communities.</p><p><strong>Objective: </strong>To examine how peer education supports breast cancer prevention in communities by exploring its delivery methods, impact on knowledge and behaviour and the cultural and practical factors that shape its effectiveness.</p><p><strong>Methods: </strong>A narrative review was conducted to explore the role of community-based peer education in breast cancer prevention. Relevant studies published between 2010 and 2025 were identified through a systematic search of six databases (CINAHL, PubMed, Web of Science, Embase, Medline and APA PsycINFO) using specific keywords. After screening and applying inclusion and exclusion criteria, data were extracted from selected studies and thematically analysed to identify patterns, benefits and challenges of peer education interventions.</p><p><strong>Result: </strong>Out of 818 studies initially retrieved, only 18 met the eligibility criteria and were reviewed, covering diverse locations and participant groups, mostly from high-income countries. The studies showed that peer education delivered through various methods and tailored to cultural contexts significantly improved breast cancer awareness, screening behaviours and community engagement, though challenges like role confusion, cultural barriers and logistical issues were also reported.</p><p><strong>Conclusion: </strong>This review concludes that peer education is an effective, adaptable strategy for promoting breast cancer prevention in community settings, especially among underserved populations.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"20 ","pages":"2108"},"PeriodicalIF":1.5,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}